Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
独立董事关于公司2021年度对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees for the fiscal year 2021. It references specific legal and regulatory frameworks related to company law, securities law, and stock exchange listing rules. The content focuses on the independent directors' review and opinion on the company's external guarantees, including amounts and compliance with laws, rather than presenting full financial statements or audit results. The document length is relatively short (2183 characters), and it is a specialized statement rather than a full audit report or annual report. This type of document aligns best with an Audit Report / Information (AR) category, as it is a standalone audit-related opinion on a specific financial aspect (external guarantees) without being a full annual report or interim report. FY 2021
2022-03-29 Chinese
深圳微芯生物科技股份有限公司公司章程（2022年3月修订）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Shenzhen Chipscreen Biosciences Co., Ltd. It contains detailed provisions about the company's organizational structure, shareholder rights, share issuance, share transfer, board of directors, management, financial accounting, profit distribution, and other governance matters. It is a comprehensive governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial statement, or any other type of financial or regulatory filing. Instead, it is a governance document outlining the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), and it is not a mere announcement or certification, so it is not RPA or RNS.
2022-03-29 Chinese
独立董事关于第二届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various company matters discussed at the 15th meeting of the second board of directors. It covers opinions on the 2021 annual profit distribution plan, internal control evaluation report, use of raised funds, remuneration for directors, supervisors, and senior management, and the reappointment of the audit firm for 2022. The document references the 2021 annual shareholders meeting and related proposals to be submitted there. It does not contain full financial statements or detailed financial data but rather opinions and approvals related to governance and compliance matters. This type of document is typically classified under Board/Management Information (MANG) as it relates to board meeting matters and management decisions rather than a full annual report or audit report.
2022-03-29 Chinese
关于召开2021年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of Shenzhen Microchip Biotechnology Co., Ltd. It includes the date, voting methods, meeting agenda items, and instructions for shareholders to participate and vote. The document does not contain financial statements or results but rather the announcement and procedural details for the AGM. It also includes an authorization proxy form for shareholders to delegate voting rights. The document length is 3537 characters, which is relatively short and consistent with an AGM notice rather than a full annual report or other financial filing. Therefore, this document fits the category of AGM Information (AGM-R).
2022-03-29 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司2021年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities firm (安信证券股份有限公司) regarding the 2021 annual special audit opinion on the deposit and use of raised funds by Shenzhen Microchip Biotechnology Co., Ltd. It includes detailed financial figures about the amount raised, usage, balances, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines and includes an auditor's verification opinion. The content focuses on the management and use of funds raised through an IPO and their compliance with relevant regulations. This type of document is a specialized audit or verification report on fundraising and fund usage, not a full annual report or earnings release. It is not a simple announcement or certification but a substantive audit-related report. Therefore, it fits best under the category Audit Report / Information (AR). FY 2021
2022-03-29 Chinese
2021年度内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '2021 年度内部控制审计报告' which translates to '2021 Annual Internal Control Audit Report' for Shenzhen Microchip Biotechnology Co., Ltd. It is issued by KPMG Huazhen LLP, a registered accounting firm, and contains an audit opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2021. The document includes detailed auditor responsibilities, company responsibilities, and an explicit audit opinion on internal control effectiveness. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. The document is not a full annual report (10-K), nor is it a brief announcement or certification. It contains substantive audit content and opinion, fitting the AR category. FY 2021
2022-03-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.